The FDA approved lirafugratinib in FGFR2+ cholangiocarcinoma and belzutifan plus lenvatinib in advanced ccRCC, and more.
|Videos|November 16, 2017
Dr. Lara on the FDA Approval of Adjuvant Sunitinib in RCC
Author(s)Primo N. Lara Jr, MD
Primo N. Lara Jr, MD, associate director for translational research, UC Davis Comprehensive Cancer Center, discusses the FDA approval of adjuvant sunitinib (Sutent) for high-risk patients with renal cell carcinoma (RCC).
Advertisement
Primo N. Lara Jr, MD, associate director for translational research, UC Davis Comprehensive Cancer Center, discusses the FDA approval of adjuvant sunitinib (Sutent) for high-risk patients with renal cell carcinoma (RCC).
Advertisement
Related to this article
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
The FDA has approved belzutifan (Welireg) plus lenvatinib (Lenvima) for use in patients with advanced renal cell carcinoma with a clear cell component after PD-1 or PD-L1 inhibition.
Advertisement
Advertisement
Trending on OncLive
1
Savolitinib Plus Osimertinib NDA Submitted to FDA for MET-Driven, EGFR-Mutated NSCLC After EGFR TKI
2
Calculating the Real Cost of False Positive Findings in Cancer Screening
3
FDA Grants Priority Review to Elinzanetant for Endocrine Therapy–Associated Vasomotor Symptoms in HR+ Breast Cancer
4
Cilta-Cel Shows Long-Term Treatment-Free Remissions in Lenalidomide-Refractory Myeloma
5